Rafaelle Lancelotta

Rebecca Lancelotta (publishing as R. Lancelotta) is a clinical researcher active in contemporary psychedelic science with a focus on naturalistic and prospective studies of fast-acting tryptamines and classic phenethylamines, and on methodological synthesis in the field. Her empirical work includes observational and prospective examinations of 5‑methoxy‑N,N‑dimethyltryptamine (5‑MeO‑DMT) administered in naturalistic group settings (including inhalation of toad secretion and synthetic formulations), reporting associations with reductions in depressive and anxiety symptoms, sustained improvements in life satisfaction and mindfulness-related capacities, and analyses of mystical-type experiences compared with psilocybin. She has also investigated naturalistic mescaline use and its relationship with self-reported psychiatric improvements and enduring positive life changes.

In addition to primary data collection, Lancelotta has contributed to broader evidence synthesis and conceptual scholarship in the psychedelic literature, including co-authorship on a meta-analysis of placebo-controlled trials of psychedelic-assisted therapy and work on the concept and practice of psychedelic integration. Her prospective laboratory-like inhalation work has examined peripheral biomarkers (salivary IL‑6, cortisol), affective outcomes and non-judgemental awareness, reflecting an interest in bridging subjective, clinical and biological endpoints. Lancelotta’s research is connected with the Center for Psychedelic Drug Research and Education (College of Social Work, Ohio State University) and situates naturalistic findings within emerging clinical and harm‑reduction frameworks.